{"gene":"ITM2B","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1999,"finding":"A single base substitution at the stop codon of BRI generates a longer open reading frame producing a 277-residue precursor; furin-like proteolytic cleavage releases the 34 C-terminal amino acids as the ABri amyloid peptide, establishing the mechanism by which the FBD mutation causes amyloid generation.","method":"Molecular cloning, sequencing, restriction enzyme analysis, antibody characterization of isolated amyloid fibrils","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — discovery paper with molecular cloning, peptide isolation, restriction enzyme validation, and antibody recognition; independently replicated in multiple subsequent studies","pmids":["10391242"],"is_preprint":false},{"year":2000,"finding":"A 10-nucleotide duplication in the 3' region of BRI2 causes a frameshift generating a larger precursor; furin cleavage releases the 34 C-terminal amino acid ADan peptide, which is deposited as amyloid in familial Danish dementia, establishing the same proteolytic release mechanism for a second BRI2 mutation.","method":"N-terminal sequence analysis of isolated amyloid fibrils, molecular genetic analysis, sequencing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct peptide sequencing from patient amyloid fibrils plus molecular genetic characterization; replicated by subsequent studies","pmids":["10781099"],"is_preprint":false},{"year":2000,"finding":"BRI2 is constitutively processed by furin, which cleaves between residues 243 and 244 to release the C-terminal peptide; furin is the most efficient proprotein convertase for this processing, and the mutant BRI-L precursor generates elevated levels of peptides compared to wild-type.","method":"Cell-based expression of BRI and BRI-L with furin inhibitor (alpha1-antitrypsin Portland), comparison of multiple proprotein convertases (furin, PACE4, PC6A, PC6B, LPC)","journal":"Annals of the New York Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro processing assay with furin inhibitor and multiple convertases; replicated by Kim et al. 2001 (PMID 11709554)","pmids":["11193182","11709554"],"is_preprint":false},{"year":2001,"finding":"Furin processes both BRI and BRI-L (FBD mutant) and BRI-D (FDD mutant); the ADan peptide accumulates predominantly in intracellular compartments whereas ABri is detected both intracellularly and in the medium, suggesting intracellular accumulation drives neuronal damage.","method":"Inducible expression with furin inhibitor alpha1-antitrypsin Portland, comparison of proprotein convertases, intracellular/extracellular peptide detection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including furin inhibition and subcellular peptide localization; consistent with Kim et al. 2000","pmids":["11709554"],"is_preprint":false},{"year":2005,"finding":"BRI2 physically interacts with APP (amyloid-beta precursor protein); the interaction requires the transmembrane domain region (residues 648–719 of APP751 and residues 46–106 of BRI2), occurs in cis on the same cell membrane, and BRI2 expression inhibits APP processing, reducing secreted Abeta and AID levels.","method":"Co-immunoprecipitation in transfected and non-transfected cells, deletion mutagenesis, Abeta ELISA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with deletion mutants and functional Abeta measurement; independently replicated by Fotinopoulou et al. 2005 (PMID 16027166)","pmids":["15983050","16027166"],"is_preprint":false},{"year":2005,"finding":"BRI2 interacts with APP via regions encompassing their full transmembrane domains; BRI2 presence increases cellular APP levels and beta-secretase-generated CTFs while decreasing alpha-secretase-generated CTFs and total secreted Abeta, indicating BRI2 modulates secretase access to APP.","method":"Co-immunoprecipitation in transfected HEK cells and primary neurons, deletion mutagenesis, Western blotting of APP processing fragments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — deletion mapping Co-IP plus multiple APP fragment readouts; consistent with Matsuda et al. 2005","pmids":["16027166"],"is_preprint":false},{"year":2007,"finding":"BRI2 undergoes regulated intramembrane proteolysis: (1) ADAM10 sheds the BRI2 ectodomain (BRICHOS domain) into the extracellular space; (2) the remaining membrane-bound N-terminal fragment is then cleaved intramembranally by SPPL2a and SPPL2b (but not SPP or SPPL3), producing an intracellular domain and a secreted low-molecular-weight C-terminal peptide.","method":"Expression of all SPP/SPPL family members including loss-of-function variants in cells, Western blotting, co-expression with dominant-negative ADAM10","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic gain/loss-of-function with all family members; two-step cleavage mechanism established with multiple readouts","pmids":["17965014"],"is_preprint":false},{"year":2008,"finding":"BRI2 restricts docking of gamma-secretase to APP and blocks alpha- and beta-secretase access to their APP cleavage sequences; gene targeting (BRI2 knockout) increases Abeta levels in AD mouse models while transgenic BRI2 overexpression reduces them, establishing BRI2 as a physiological suppressor of Abeta production.","method":"Gene targeting (knockout mice), transgenic overexpression, in vivo Abeta quantification, cell-based secretase access assays","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain- and loss-of-function in vivo with defined molecular mechanism (secretase docking); replicated by Kim et al. 2008","pmids":["18753367"],"is_preprint":false},{"year":2008,"finding":"Wild-type BRI2 reduces cerebral Abeta deposition in APP mouse models; the 23 amino acid peptide Bri2-23, released from BRI2 by normal furin processing, is present in human CSF, inhibits Abeta aggregation in vitro, and mediates the anti-amyloidogenic effect in vivo.","method":"Somatic brain transgenics, in vitro Abeta aggregation assay, CSF peptide detection","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic approach with in vitro aggregation validation; multiple orthogonal readouts","pmids":["18524908"],"is_preprint":false},{"year":2008,"finding":"BRI2 forms homodimers in cells via both non-covalent interactions and disulfide bridges between cysteines at position 89; dimers form in the ER and are present at the cell surface and in mouse brain.","method":"Non-reducing SDS-PAGE, co-immunoprecipitation, site-directed mutagenesis of Cys89, cell fractionation, mouse brain analysis","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis identifying specific cysteine plus Co-IP and fractionation; single lab","pmids":["18440095"],"is_preprint":false},{"year":2009,"finding":"Mature BRI2 (but not immature forms) is transported to the plasma membrane and endosomes where it selectively interacts with mature APP; mature BRI2 inhibits APP processing by alpha-, beta-, and gamma-secretases specifically at the plasma membrane and in endocytic compartments.","method":"Live-cell imaging (FRAP), co-immunoprecipitation of mature vs. immature forms, subcellular fractionation, pharmacological inhibition of secretases","journal":"Neurobiology of aging","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (imaging, Co-IP with maturation distinction, fractionation, functional assays); single lab but rigorous","pmids":["19748705"],"is_preprint":false},{"year":2009,"finding":"The extracellular BRICHOS domain of Bri2 (residues 90–236) binds to the ABri23 peptide and to Abeta1-40, and inhibits Abeta1-40 aggregation and fibril formation in vitro.","method":"Recombinant protein binding assay, Thioflavin T fibril formation assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding with recombinant protein plus functional aggregation assay; single lab, two orthogonal methods","pmids":["20036644"],"is_preprint":false},{"year":2010,"finding":"The British BRI2 mutation drastically reduces expression of mature BRI2 protein in knock-in mice and in human FBD brains; this loss of BRI2 function causes severe hippocampal memory deficits independently of cerebral amyloidosis or tauopathy, as shown by the identical memory deficit in Bri2+/- heterozygous mice.","method":"Knock-in mouse model (FBD-KI), Bri2+/- heterozygous mice, behavioral memory testing, Western blotting for BRI2 protein levels in mouse and human brain","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetically congruous KI model plus heterozygous control with behavioral and biochemical readouts; loss-of-function phenotype defined","pmids":["21048150"],"is_preprint":false},{"year":2011,"finding":"APP/BRI2 complexes are reduced in synaptic membranes of FDD knock-in mice; APP haplodeficiency rescues memory and synaptic plasticity deficits in FDD-KI mice, establishing a functional genetic epistasis between BRI2 and APP in which BRI2 inhibits APP processing and APP metabolites mediate the synaptic/memory pathology.","method":"FDD knock-in x APP heterozygous cross (genetic epistasis), co-immunoprecipitation of synaptic membrane fractions, LTP measurements, behavioral memory testing","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with mechanistic Co-IP and electrophysiology; multiple orthogonal methods in one study","pmids":["21587206"],"is_preprint":false},{"year":2011,"finding":"BRI2 is N-glycosylated at asparagine 170; mutation of Asn170 to alanine reduces BRI2 trafficking to the cell surface and its steady-state plasma membrane levels, but does not affect cleavage by furin or ADAM10.","method":"Tunicamycin treatment, site-directed mutagenesis (N170A), cell surface biotinylation, pulse-chase 35S-methionine labeling","journal":"Glycobiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mutagenesis combined with pulse-chase and biotinylation; two orthogonal methods establishing glycosylation's specific role in trafficking but not processing","pmids":["21752865"],"is_preprint":false},{"year":2011,"finding":"BRI2 overexpression reduces extracellular Abeta by increasing levels of secreted insulin-degrading enzyme (IDE), a major Abeta-degrading protease; this effect is observed even with BRI2 lacking its C-terminal 23 amino acid peptide, suggesting BRI2 acts as a receptor that regulates IDE secretion.","method":"BRI2 overexpression in cells and AD mouse model, IDE ELISA and activity assay, Abeta measurement, BRI2 deletion constructs","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion constructs plus IDE functional measurements; single lab, multiple readouts","pmids":["21873424"],"is_preprint":false},{"year":2011,"finding":"The alpha-helical content of the BRI2 transmembrane domain (TMD) governs efficiency of intramembrane cleavage by SPPL2b: higher alpha-helical content reduces cleavage efficiency; a GXXXG dimerization motif has only minor influence; only one of four conserved intramembrane glycine residues significantly affects TMD secondary structure and intramembrane processing.","method":"Site-directed mutagenesis of TMD residues, circular dichroism spectroscopy, cell-based cleavage assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with CD spectroscopy and functional cleavage assay; mechanistic dissection of TMD determinants","pmids":["22194595"],"is_preprint":false},{"year":2013,"finding":"BRI2 interacts with BACE1 and decreases its cellular levels by promoting lysosomal (not proteasomal) degradation of BACE1; BRI2 also reduces BACE1 mRNA levels by ~50%, thereby reducing beta-cleavage of APP.","method":"Co-immunoprecipitation, lysosomal/proteasomal inhibitor experiments, RT-PCR for BACE1 mRNA, Western blotting of sAPPbeta","journal":"Current Alzheimer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus pharmacological dissection of degradation pathway and mRNA measurement; single lab, multiple orthogonal methods","pmids":["23701002"],"is_preprint":false},{"year":2015,"finding":"BRI2 is a phosphoprotein and a protein phosphatase 1 (PP1) interacting protein; the BRI2:PP1 complex is formed in vitro and in vivo; disruption of the PP1-binding motif increases BRI2 phosphorylation; phosphorylated full-length BRI2 promotes formation of neuritic processes while the BRI2 N-terminal fragment (generated by ADAM10 processing) promotes neurite elongation.","method":"Co-immunoprecipitation in vitro and in vivo, PP1-binding motif mutagenesis, phosphorylation assays, ADAM10 inhibitor treatment, neurite outgrowth measurements in SH-SY5Y cells","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — validated Co-IP plus mutagenesis and functional neurite assay; single lab, multiple orthogonal methods","pmids":["26515131"],"is_preprint":false},{"year":2017,"finding":"Bri2 BRICHOS domain monomers potently prevent neuronal network toxicity of Abeta42, while dimers strongly suppress Abeta fibril formation; high-molecular-weight oligomers efficiently inhibit non-fibrillar protein aggregation; these qualitatively distinct chaperone activities are governed by the quaternary assembly state of the BRICHOS domain.","method":"Recombinant Bri2 BRICHOS in defined oligomeric states, ThT fibril formation assays, hippocampal network oscillation electrophysiology, Drosophila in vivo model, electron microscopy","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (in vitro aggregation, electrophysiology, in vivo), dissection by defined assembly states; replicated and extended in subsequent work","pmids":["29234026"],"is_preprint":false},{"year":2017,"finding":"BRI2 phosphorylation state (regulated by the BRI2:PP1 complex) is an important regulatory mechanism for its proteolytic processing and neuritogenic role; phosphorylated full-length BRI2 is important for neuritic process formation, while BRI2 NTF (produced by ADAM10 processing) promotes neurite elongation.","method":"PP1-binding motif mutant transfection in SH-SY5Y cells, ADAM10 inhibitor treatment, neurite outgrowth quantification, Western blotting","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis combined with pharmacological inhibition and functional assay; single lab","pmids":["28176357"],"is_preprint":false},{"year":2018,"finding":"The BRICHOS domain of Bri2 inhibits IAPP fibril formation in vitro and redirects IAPP into amorphous aggregates; Bri2 colocalizes with IAPP intracellularly in human beta cells; siRNA knockdown of endogenous Bri2 increases sensitivity to metabolic stress and cell death; overexpression of Bri2 BRICHOS is protective against IAPP toxicity in human beta cells and in a Drosophila model.","method":"siRNA knockdown, Bri2 overexpression, in vitro ThT fibril assay, cell viability assay, Drosophila survival assay, immunofluorescence colocalization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function in two experimental systems (human cells and Drosophila) plus in vitro mechanistic assay; multiple orthogonal approaches","pmids":["29507232"],"is_preprint":false},{"year":2019,"finding":"ITM2B/BRI2 has dual presynaptic and postsynaptic roles in glutamatergic transmission: conditional deletion of Itm2b in CA3 neurons decreases spontaneous glutamate release probability and increases short-term synaptic facilitation, while deletion in CA1 neurons decreases AMPAR-mediated postsynaptic responses.","method":"Conditional neuron-specific Cre-mediated Itm2b knockout in hippocampal Schaffer-collateral pathway (CA3, CA1, or both), electrophysiology (spontaneous EPSCs, AMPAR responses, short-term plasticity)","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with defined electrophysiological phenotypes dissecting pre- vs. postsynaptic contributions","pmids":["30890756"],"is_preprint":false},{"year":2019,"finding":"ITM2B physically interacts with the urate transporter GLUT9 (SLC2A9), identified by dual-membrane yeast two-hybrid, and confirmed by co-immunoprecipitation in transfected HEK293T cells; ITM2B inhibits GLUT9-mediated urate uptake and stimulates urate efflux; ITM2B variants linked to familial Danish dementia significantly attenuate inhibition of GLUT9-mediated urate influx.","method":"Dual-membrane yeast two-hybrid, co-immunoprecipitation in HEK293T cells and Xenopus oocytes, urate transport assays in oocytes, glycosylation mutant analysis","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus functional transport assay; single lab, multiple orthogonal methods","pmids":["31695625"],"is_preprint":false},{"year":2020,"finding":"FDD and FBD pathogenic mutations in ITM2b alter maturation of BRI2 resulting in reduced levels of functional mature BRI2 protein at synapses, leading to reduced spontaneous glutamate release, decreased AMPAR-mediated responses, and increased short-term synaptic facilitation — phenotypes matching those of Itm2b knockout mice, establishing loss of BRI2 synaptic function as a pathogenic mechanism.","method":"FDD and FBD knock-in mice, in vivo and in vitro maturation assays, electrophysiology in hippocampal slices","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in models genetically congruous to human disease with biochemical and electrophysiological readouts; consistent with prior work","pmids":["33172889"],"is_preprint":false},{"year":2020,"finding":"NRBP1, a substrate receptor of a heterodimeric Cullin-RING ubiquitin ligase (CRL) containing both Cul2 and Cul4A, targets BRI2 (and BRI3) for ubiquitin-mediated degradation; NRBP1 dimerizes and assembles the CRL through its BC-box and cryptic H-box; chaperone-like TSC22D3 and TSC22D4 enhance NRBP1 CRL formation; NRBP1 knockdown in neuronal cells increases BRI2/BRI3 abundance and significantly reduces Abeta production.","method":"Co-immunoprecipitation, ubiquitination assays, NRBP1 knockdown in neuronal cells, Abeta ELISA, mass spectrometry interactome","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — identified CRL components by MS, validated by Co-IP, mutagenesis of BC-box/H-box, and loss-of-function with functional Abeta readout","pmids":["32160551"],"is_preprint":false},{"year":2020,"finding":"A R221E mutant of Bri2 BRICHOS forms stable monomers; introducing R221E partially disassembles wild-type Bri2 BRICHOS oligomers into monomers, potentiating their ability to prevent Abeta42 neurotoxicity to neuronal network activity, demonstrating that the chaperone activity of endogenous Bri2 BRICHOS can be augmented by modulating assembly state.","method":"Site-directed mutagenesis, analytical ultracentrifugation, hippocampal network oscillation electrophysiology, ThT fibril formation assay","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis defining oligomeric state plus functional electrophysiology readout; single lab but multiple orthogonal methods","pmids":["31959875"],"is_preprint":false},{"year":2002,"finding":"ITM2B(s), a short cytoplasmic/mitochondrial isoform of ITM2B containing a BH3 domain, induces apoptosis upon IL-2 deprivation and interacts with the anti-apoptotic protein Bcl-2; mutation of the critical L and D residues within the BH3 domain abolishes its pro-apoptotic activity.","method":"Cloning and overexpression of ITM2B(s), co-immunoprecipitation with Bcl-2, BH3 domain mutagenesis, cell viability assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with Bcl-2 and BH3 mutagenesis establishing domain requirement; single lab, two orthogonal methods","pmids":["12082633"],"is_preprint":false},{"year":2024,"finding":"BRI2 directly interacts with TREM2 protein (confirmed by cell-free ectodomain binding with recombinant proteins), inhibits alpha-secretase-mediated TREM2 processing in cells and in vivo; constitutive and microglial-specific Itm2b-KO mice show increased TREM2-CTF and sTREM2; BRI2 also boosts Trem2 mRNA expression and influences Trem2 protein levels through alpha-secretase-independent pathways.","method":"Cell-free direct binding of recombinant BRI2 and TREM2 ectodomains, co-immunoprecipitation in heterologous cells, constitutive and conditional (microglial-specific) Itm2b knockout mice, single-cell RNA-sequencing, Western blotting and ELISA for TREM2 processing products","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-free direct binding plus multiple in vivo genetic models (constitutive KO and cell-type-specific KO) with multiple processing readouts","pmids":["38347225"],"is_preprint":false},{"year":2024,"finding":"Myelin basic protein (MBP) covers a significant portion of the Bri2 ectodomain (including the furin cleavage site) and attenuates furin-mediated Bri2 C-terminal peptide cleavage; MBP co-expression also restricts Bri2 membrane trafficking independently of the furin cleavage suppression.","method":"Molecular dynamics simulation of MBP-Bri2 complex, co-expression of MBP with Bri2 and mutants in mammalian cells, Western blotting for processing products, subcellular localization analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cell-based functional assay with localization readout supported by molecular dynamics; single lab, in silico plus cell-based","pmids":["38473856"],"is_preprint":false},{"year":2025,"finding":"Using a massively parallel yeast-based assay, the amyloid-forming core of ADan fibrils was mapped to positions 20–26 of the C-terminal peptide (where stop-loss extension occurs); ~32% of random C-terminal extensions of Bri2 can nucleate amyloid, showing the Bri2 C-terminus contains an incomplete amyloid motif that becomes amyloidogenic upon extension — providing a mechanism for pathogenic stop-loss mutations.","method":"Yeast-based massively parallel amyloid formation assay (676 ADan substitutions and ~18,000 random C-terminal extensions), systematic amyloid scoring","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis at scale with quantitative amyloid readout defining the amyloid core; single study but high-throughput and rigorous","pmids":["40314981"],"is_preprint":false}],"current_model":"ITM2B/BRI2 is a type II transmembrane protein that undergoes sequential proteolytic processing: furin cleaves the C-terminus to release the normal Bri2-23 peptide (or pathological ABri/ADan peptides from mutant precursors), ADAM10 sheds the ectodomain (BRICHOS domain), and SPPL2a/SPPL2b perform intramembrane cleavage of the remaining N-terminal fragment; mature BRI2 directly binds APP at their transmembrane domains in cis on the plasma membrane and in endosomes, sterically blocking alpha-, beta-, and gamma-secretase access to APP to suppress Abeta production, and also directly binds and inhibits processing of TREM2 by alpha-secretase in microglia; the released BRICHOS domain acts as an assembly-state-dependent molecular chaperone (monomers suppress Abeta toxicity, dimers suppress fibril formation, oligomers inhibit non-fibrillar aggregation); BRI2 is additionally regulated post-translationally by N-glycosylation at Asn170 (required for plasma membrane trafficking), phosphorylation governed by a BRI2:PP1 complex (which controls neuritogenesis and processing), and ubiquitin-mediated degradation via the NRBP1-containing CRL2/CRL4A ligase; loss of BRI2 function impairs both presynaptic glutamate release and postsynaptic AMPAR responses, causing synaptic and memory deficits, while pathogenic FBD/FDD mutations reduce mature BRI2 protein levels, identifying loss-of-function as a key pathogenic mechanism independent of amyloid deposition."},"narrative":{"mechanistic_narrative":"ITM2B/BRI2 is a type II transmembrane protein that physiologically suppresses amyloidogenic processing and supports synaptic function in the brain [PMID:18753367, PMID:30890756]. Mature BRI2 reaches the plasma membrane and endosomes and binds APP in cis through their transmembrane domains, sterically restricting alpha-, beta-, and gamma-secretase access to APP and thereby lowering Abeta production [PMID:15983050, PMID:16027166, PMID:19748705]; genetic loss of BRI2 raises Abeta in vivo while overexpression lowers it [PMID:18753367, PMID:18524908]. BRI2 also broadens its amyloid-suppressing reach by reducing BACE1 levels, by acting as a receptor that elevates secreted insulin-degrading enzyme, and by directly binding TREM2 in microglia to limit its alpha-secretase processing [PMID:23701002, PMID:21873424, PMID:38347225]. BRI2 is matured by sequential proteolysis: furin cleaves the C-terminus to liberate the anti-aggregant Bri2-23 peptide, ADAM10 sheds the BRICHOS ectodomain, and SPPL2a/SPPL2b carry out intramembrane cleavage of the residual N-terminal fragment [PMID:11193182, PMID:11709554, PMID:17965014, PMID:18524908]. The released BRICHOS domain is an assembly-state-dependent chaperone whose monomers block Abeta42 neurotoxicity, dimers suppress fibril formation, and oligomers inhibit non-fibrillar aggregation, with activity extending to IAPP [PMID:29234026, PMID:31959875, PMID:29507232]. BRI2 function and trafficking are tuned by N-glycosylation at Asn170, by a BRI2:PP1 phosphorylation complex that governs neuritogenesis, and by NRBP1-containing CRL2/CRL4A-mediated ubiquitin degradation [PMID:21752865, PMID:26515131, PMID:32160551]. The familial British and Danish dementia mutations cause C-terminal stop-loss/frameshift extensions that release the amyloidogenic ABri and ADan peptides via the same furin step while drastically reducing mature functional BRI2 at synapses, establishing loss of BRI2 synaptic function—impaired glutamate release and AMPAR responses—as a pathogenic mechanism independent of amyloid deposition [PMID:10391242, PMID:10781099, PMID:21048150, PMID:33172889].","teleology":[{"year":1999,"claim":"Established how a BRI2 disease mutation produces amyloid, answering what molecular lesion underlies familial British dementia.","evidence":"Molecular cloning, sequencing, and antibody analysis of isolated amyloid fibrils identifying a stop-codon substitution that extends the ORF and a furin-released 34-residue ABri peptide","pmids":["10391242"],"confidence":"High","gaps":["Did not define BRI2's normal physiological function","Did not establish whether amyloid or protein loss drives disease"]},{"year":2000,"claim":"Generalized the proteolytic-release mechanism to a second mutation, showing a frameshift duplication produces the ADan amyloid peptide in familial Danish dementia.","evidence":"N-terminal sequencing of patient amyloid fibrils plus molecular genetic analysis","pmids":["10781099"],"confidence":"High","gaps":["Subcellular site of peptide accumulation not resolved","Normal BRI2 function still unknown"]},{"year":2000,"claim":"Identified furin as the constitutive protease cleaving BRI2 and showed mutant precursor yields elevated peptide, defining the enzymatic step that liberates the C-terminal peptides.","evidence":"Cell-based expression of BRI/BRI-L with furin inhibitor and comparison across proprotein convertases; replicated subcellular localization showing ADan accumulates intracellularly","pmids":["11193182","11709554"],"confidence":"High","gaps":["Did not address whether furin processing is regulated","Other proteolytic steps not yet identified"]},{"year":2002,"claim":"Proposed a pro-apoptotic role for a short ITM2B isoform, raising the question of whether BRI2 participates in cell death regulation.","evidence":"Overexpression of ITM2B(s), Co-IP with Bcl-2, and BH3-domain mutagenesis with viability assays","pmids":["12082633"],"confidence":"Medium","gaps":["Physiological relevance of the short isoform not established","Not linked to the neuronal/synaptic functions later defined","Single lab, not independently confirmed"]},{"year":2005,"claim":"Revealed BRI2's normal function as a cis-binding inhibitor of APP, answering how it could suppress Abeta production.","evidence":"Reciprocal Co-IP with deletion mutants mapping the transmembrane interaction and Abeta ELISA/CTF Western blots in cells and primary neurons","pmids":["15983050","16027166"],"confidence":"High","gaps":["In vivo significance not yet demonstrated","Which secretases are blocked at which compartments unresolved"]},{"year":2007,"claim":"Defined the full maturation pathway by identifying ADAM10 ectodomain shedding followed by SPPL2a/SPPL2b intramembrane cleavage.","evidence":"Systematic gain/loss-of-function across all SPP/SPPL family members and dominant-negative ADAM10 with Western blot fragment readouts","pmids":["17965014"],"confidence":"High","gaps":["Functions of the released fragments not yet defined","Regulation of these cleavages unknown"]},{"year":2008,"claim":"Demonstrated in vivo that BRI2 is a physiological Abeta suppressor and that the furin-released Bri2-23 peptide mediates the anti-amyloidogenic effect.","evidence":"BRI2 knockout and transgenic overexpression in AD mouse models, in vitro Abeta aggregation assays, secretase-access assays, and CSF peptide detection","pmids":["18753367","18524908"],"confidence":"High","gaps":["Did not separate amyloid-suppression from any independent BRI2 functions","Synaptic role not addressed"]},{"year":2009,"claim":"Refined the mechanism to mature BRI2 acting at the plasma membrane/endosomes, and showed BRI2 homodimerizes via Cys89.","evidence":"FRAP imaging, maturation-discriminating Co-IP and fractionation, and Cys89 mutagenesis on non-reducing gels","pmids":["19748705","18440095"],"confidence":"High","gaps":["Functional consequence of dimerization for APP inhibition not defined","Dimerization data from single lab"]},{"year":2010,"claim":"Separated amyloid deposition from disease by showing the British mutation reduces mature BRI2 and that haploinsufficiency alone causes memory deficits.","evidence":"FBD knock-in and Bri2+/- heterozygous mice with behavioral testing and Western blots in mouse and human FBD brain","pmids":["21048150"],"confidence":"High","gaps":["Molecular basis of the memory deficit not yet mapped to a pathway","Synaptic mechanism not resolved"]},{"year":2011,"claim":"Established genetic epistasis placing APP metabolites downstream of BRI2 loss in synaptic/memory pathology and added trafficking, IDE, and BACE1 regulatory layers.","evidence":"FDD-KI x APP-heterozygous cross with LTP and behavior; Asn170 glycosylation mutagenesis with biotinylation/pulse-chase; IDE deletion-construct experiments; BRICHOS-Abeta binding/ThT assays","pmids":["21587206","21752865","21873424","20036644","22194595"],"confidence":"High","gaps":["Relative contributions of direct APP inhibition vs IDE/BACE1 routes not quantified","Some regulatory mechanisms from single labs"]},{"year":2013,"claim":"Showed BRI2 lowers BACE1 by promoting lysosomal degradation and reducing its mRNA, broadening how BRI2 limits beta-cleavage of APP.","evidence":"Co-IP, lysosomal/proteasomal inhibitor experiments, BACE1 RT-PCR, and sAPPbeta Western blotting","pmids":["23701002"],"confidence":"Medium","gaps":["Mechanism linking BRI2 to BACE1 transcription unknown","Single lab"]},{"year":2017,"claim":"Resolved BRICHOS chaperone behavior as assembly-state-dependent and linked phosphorylation to processing and neuritogenesis.","evidence":"Recombinant BRICHOS in defined oligomeric states with ThT, hippocampal network electrophysiology, Drosophila, and EM; PP1-binding-motif mutagenesis with neurite assays","pmids":["29234026","28176357"],"confidence":"High","gaps":["In vivo relevance of specific BRICHOS assembly states not fully established","Phosphorylation findings from single lab"]},{"year":2018,"claim":"Extended BRICHOS chaperone activity to IAPP and showed endogenous Bri2 protects beta cells from amyloid toxicity, indicating a general anti-amyloid function.","evidence":"siRNA knockdown and BRICHOS overexpression in human beta cells and Drosophila, in vitro ThT, and colocalization","pmids":["29507232"],"confidence":"High","gaps":["Endogenous relevance to diabetes pathology in humans not established","Mechanism of intracellular Bri2-IAPP colocalization unclear"]},{"year":2019,"claim":"Defined dual presynaptic and postsynaptic roles for ITM2B in glutamatergic transmission and added a candidate non-amyloid interactor, GLUT9.","evidence":"Cell-type-specific conditional Itm2b knockout in CA3/CA1 with electrophysiology; dual-membrane Y2H and Co-IP plus urate transport assays for GLUT9","pmids":["30890756","31695625"],"confidence":"Medium","gaps":["Molecular effector linking BRI2 to glutamate release and AMPAR responses unknown","GLUT9 interaction from single lab without in vivo confirmation"]},{"year":2020,"claim":"Unified loss-of-function as the disease mechanism by showing FDD/FBD mutations reduce mature synaptic BRI2 and phenocopy knockout; identified NRBP1-CRL ubiquitin degradation and augmentable BRICHOS chaperone state.","evidence":"FDD/FBD knock-in mice with maturation assays and hippocampal-slice electrophysiology; NRBP1 CRL component MS/Co-IP/ubiquitination with Abeta readout; R221E BRICHOS monomerization with AUC and electrophysiology","pmids":["33172889","32160551","31959875"],"confidence":"High","gaps":["Upstream signals regulating NRBP1-mediated BRI2 turnover unknown","Therapeutic feasibility of modulating BRICHOS assembly in vivo untested"]},{"year":2024,"claim":"Expanded BRI2's substrate repertoire to TREM2 in microglia and identified MBP as a regulator of furin processing and trafficking.","evidence":"Cell-free recombinant ectodomain binding, constitutive and microglial-specific Itm2b knockouts, scRNA-seq, and TREM2 processing readouts; MBP-Bri2 molecular dynamics plus co-expression cell assays","pmids":["38347225","38473856"],"confidence":"High","gaps":["Functional consequence of BRI2-TREM2 regulation for microglial biology not fully defined","MBP regulation mechanism from a single in silico/cell study"]},{"year":2025,"claim":"Provided a sequence-level mechanism for pathogenic stop-loss mutations by mapping the ADan amyloid core and showing the Bri2 C-terminus harbors an incomplete amyloid motif that becomes amyloidogenic on extension.","evidence":"Massively parallel yeast-based amyloid assay scoring hundreds of ADan substitutions and thousands of random C-terminal extensions","pmids":["40314981"],"confidence":"High","gaps":["Yeast amyloid scores require validation in mammalian/neuronal context","Does not address how extension interacts with the loss-of-function pathway"]},{"year":null,"claim":"The molecular effectors that couple BRI2 to presynaptic glutamate release and postsynaptic AMPAR responses, and how its many regulatory inputs are integrated in vivo, remain undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No identified synaptic effector downstream of BRI2","No structure of the BRI2-APP transmembrane complex","Physiological balance among APP, TREM2, IDE, BACE1, and GLUT9 interactions not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,7,17,28]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[19,21,26]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[11,19,21]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,10,14]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[10]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[9]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[6,8]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,6,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,12,24]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[22,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[28]}],"complexes":["BRI2:PP1 complex","BRI2-APP transmembrane complex","NRBP1 CRL2/CRL4A ubiquitin ligase"],"partners":["APP","TREM2","BACE1","PP1","NRBP1","SLC2A9","BCL2","ADAM10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y287","full_name":"Integral membrane protein 2B","aliases":["Immature BRI2","imBRI2","Protein E25B","Transmembrane protein BRI","Bri"],"length_aa":266,"mass_kda":30.3,"function":"Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42 Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9Y287/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ITM2B","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ITM2B","total_profiled":1310},"omim":[{"mim_id":"616079","title":"RETINAL DYSTROPHY WITH INNER RETINAL DYSFUNCTION AND GANGLION CELL ABNORMALITIES; RDGCA","url":"https://www.omim.org/entry/616079"},{"mim_id":"614555","title":"FERM DOMAIN-CONTAINING PROTEIN 6; FRMD6","url":"https://www.omim.org/entry/614555"},{"mim_id":"609554","title":"INTEGRAL MEMBRANE PROTEIN 2C; ITM2C","url":"https://www.omim.org/entry/609554"},{"mim_id":"608239","title":"SIGNAL PEPTIDE PEPTIDASE-LIKE 2B; SPPL2B","url":"https://www.omim.org/entry/608239"},{"mim_id":"606981","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-2; GNG2","url":"https://www.omim.org/entry/606981"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Golgi apparatus","reliability":"Enhanced"},{"location":"Vesicles","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ITM2B"},"hgnc":{"alias_symbol":["BRI","E25B","E3-16","BRICD2B","BRI2"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y287","domains":[{"cath_id":"-","chopping":"85-99_110-234_245-264","consensus_level":"high","plddt":87.2028,"start":85,"end":264}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y287","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y287-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y287-F1-predicted_aligned_error_v6.png","plddt_mean":75.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ITM2B","jax_strain_url":"https://www.jax.org/strain/search?query=ITM2B"},"sequence":{"accession":"Q9Y287","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y287.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y287/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y287"}},"corpus_meta":[{"pmid":"10391242","id":"PMC_10391242","title":"A stop-codon mutation in the BRI gene associated with familial British dementia.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10391242","citation_count":386,"is_preprint":false},{"pmid":"10781099","id":"PMC_10781099","title":"A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10781099","citation_count":255,"is_preprint":false},{"pmid":"17965014","id":"PMC_17965014","title":"Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17965014","citation_count":137,"is_preprint":false},{"pmid":"15983050","id":"PMC_15983050","title":"The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15983050","citation_count":126,"is_preprint":false},{"pmid":"11159188","id":"PMC_11159188","title":"Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11159188","citation_count":117,"is_preprint":false},{"pmid":"16027166","id":"PMC_16027166","title":"BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16027166","citation_count":101,"is_preprint":false},{"pmid":"18524908","id":"PMC_18524908","title":"BRI2 (ITM2b) inhibits Abeta deposition in vivo.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18524908","citation_count":96,"is_preprint":false},{"pmid":"18753367","id":"PMC_18753367","title":"BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18753367","citation_count":88,"is_preprint":false},{"pmid":"15569154","id":"PMC_15569154","title":"Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2.","date":"2004","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/15569154","citation_count":80,"is_preprint":false},{"pmid":"29234026","id":"PMC_29234026","title":"Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29234026","citation_count":71,"is_preprint":false},{"pmid":"23663320","id":"PMC_23663320","title":"Normal cognition in transgenic BRI2-Aβ mice.","date":"2013","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/23663320","citation_count":66,"is_preprint":false},{"pmid":"19748705","id":"PMC_19748705","title":"Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles.","date":"2009","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/19748705","citation_count":62,"is_preprint":false},{"pmid":"14586629","id":"PMC_14586629","title":"Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain.","date":"2003","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/14586629","citation_count":55,"is_preprint":false},{"pmid":"29507232","id":"PMC_29507232","title":"BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29507232","citation_count":52,"is_preprint":false},{"pmid":"18410407","id":"PMC_18410407","title":"Cerebral amyloid angiopathy and parenchymal amyloid deposition in transgenic mice expressing the Danish mutant form of human BRI2.","date":"2008","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/18410407","citation_count":52,"is_preprint":false},{"pmid":"27514716","id":"PMC_27514716","title":"Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Aβ42 toxicity in Drosophila.","date":"2016","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27514716","citation_count":51,"is_preprint":false},{"pmid":"21048150","id":"PMC_21048150","title":"Memory deficits due to familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21048150","citation_count":50,"is_preprint":false},{"pmid":"19366692","id":"PMC_19366692","title":"BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19366692","citation_count":48,"is_preprint":false},{"pmid":"31959875","id":"PMC_31959875","title":"Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/31959875","citation_count":48,"is_preprint":false},{"pmid":"11290423","id":"PMC_11290423","title":"Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11290423","citation_count":48,"is_preprint":false},{"pmid":"33061450","id":"PMC_33061450","title":"G-MDSCs-Derived Exosomal miRNA-143-3p Promotes Proliferation via Targeting of ITM2B in Lung Cancer.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33061450","citation_count":48,"is_preprint":false},{"pmid":"11709554","id":"PMC_11709554","title":"Proteolytic processing of familial British dementia-associated BRI variants: evidence for enhanced intracellular accumulation of amyloidogenic peptides.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11709554","citation_count":48,"is_preprint":false},{"pmid":"21587206","id":"PMC_21587206","title":"APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21587206","citation_count":47,"is_preprint":false},{"pmid":"20036644","id":"PMC_20036644","title":"The extracellular domain of Bri2 (ITM2B) binds the ABri peptide (1-23) and amyloid beta-peptide (Abeta1-40): Implications for Bri2 effects on processing of amyloid precursor protein and Abeta aggregation.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20036644","citation_count":44,"is_preprint":false},{"pmid":"24524963","id":"PMC_24524963","title":"BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24524963","citation_count":43,"is_preprint":false},{"pmid":"21873424","id":"PMC_21873424","title":"BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21873424","citation_count":38,"is_preprint":false},{"pmid":"16612984","id":"PMC_16612984","title":"Genetic alterations of the BRI2 gene: familial British and Danish dementias.","date":"2006","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/16612984","citation_count":38,"is_preprint":false},{"pmid":"29288670","id":"PMC_29288670","title":"The suppressive effects of Britannin (Bri) on human liver cancer through inducing apoptosis and autophagy via AMPK activation regulated by ROS.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29288670","citation_count":38,"is_preprint":false},{"pmid":"32160551","id":"PMC_32160551","title":"NRBP1-Containing CRL2/CRL4A Regulates Amyloid β Production by Targeting BRI2 and BRI3 for Degradation.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32160551","citation_count":36,"is_preprint":false},{"pmid":"22194595","id":"PMC_22194595","title":"The α-helical content of the transmembrane domain of the British dementia protein-2 (Bri2) determines its processing by signal peptide peptidase-like 2b (SPPL2b).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22194595","citation_count":36,"is_preprint":false},{"pmid":"12082633","id":"PMC_12082633","title":"Proapoptotic activity of ITM2B(s), a BH3-only protein induced upon IL-2-deprivation which interacts with Bcl-2.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12082633","citation_count":33,"is_preprint":false},{"pmid":"30480246","id":"PMC_30480246","title":"The Bri2 and Bri3 BRICHOS Domains Interact Differently with Aβ42 and Alzheimer Amyloid Plaques.","date":"2018","source":"Journal of Alzheimer's disease reports","url":"https://pubmed.ncbi.nlm.nih.gov/30480246","citation_count":31,"is_preprint":false},{"pmid":"11476963","id":"PMC_11476963","title":"Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11476963","citation_count":31,"is_preprint":false},{"pmid":"20600910","id":"PMC_20600910","title":"Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20600910","citation_count":29,"is_preprint":false},{"pmid":"24026677","id":"PMC_24026677","title":"The familial dementia gene revisited: a missense mutation revealed by whole-exome sequencing identifies ITM2B as a candidate gene underlying a novel autosomal dominant retinal dystrophy in a large family.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24026677","citation_count":26,"is_preprint":false},{"pmid":"16972883","id":"PMC_16972883","title":"Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study.","date":"2006","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/16972883","citation_count":24,"is_preprint":false},{"pmid":"39468529","id":"PMC_39468529","title":"Body shape index (ABSI), body roundness index (BRI) and risk factors of metabolic syndrome among overweight and obese adults: a cross-sectional study.","date":"2024","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/39468529","citation_count":24,"is_preprint":false},{"pmid":"24473189","id":"PMC_24473189","title":"Role of BRI2 in dementia.","date":"2014","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/24473189","citation_count":23,"is_preprint":false},{"pmid":"18282158","id":"PMC_18282158","title":"Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease.","date":"2008","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18282158","citation_count":23,"is_preprint":false},{"pmid":"30890756","id":"PMC_30890756","title":"The Familial dementia gene ITM2b/BRI2 facilitates glutamate transmission via both presynaptic and postsynaptic mechanisms.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30890756","citation_count":22,"is_preprint":false},{"pmid":"31695625","id":"PMC_31695625","title":"Interaction Between ITM2B and GLUT9 Links Urate Transport to Neurodegenerative Disorders.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31695625","citation_count":22,"is_preprint":false},{"pmid":"23418567","id":"PMC_23418567","title":"Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23418567","citation_count":22,"is_preprint":false},{"pmid":"19072909","id":"PMC_19072909","title":"BRI2 as a central protein involved in neurodegeneration.","date":"2008","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/19072909","citation_count":21,"is_preprint":false},{"pmid":"26862951","id":"PMC_26862951","title":"Expression Pattern of the BCL6 and ITM2B Proteins in Normal Human Brains and in Alzheimer Disease.","date":"2017","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/26862951","citation_count":21,"is_preprint":false},{"pmid":"34480585","id":"PMC_34480585","title":"The role of the integral type II transmembrane protein BRI2 in health and disease.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/34480585","citation_count":20,"is_preprint":false},{"pmid":"30949182","id":"PMC_30949182","title":"Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30949182","citation_count":20,"is_preprint":false},{"pmid":"23701002","id":"PMC_23701002","title":"BRI2 interacts with BACE1 and regulates its cellular levels by promoting its degradation and reducing its mRNA levels.","date":"2013","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/23701002","citation_count":19,"is_preprint":false},{"pmid":"33172889","id":"PMC_33172889","title":"Danish and British dementia ITM2b/BRI2 mutations reduce BRI2 protein stability and impair glutamatergic synaptic transmission.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33172889","citation_count":18,"is_preprint":false},{"pmid":"33303867","id":"PMC_33303867","title":"Functionalization of amyloid fibrils via the Bri2 BRICHOS domain.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33303867","citation_count":17,"is_preprint":false},{"pmid":"16535175","id":"PMC_16535175","title":"Uptake of Benzoic Acid and Chloro-Substituted Benzoic Acids by Alcaligenes denitrificans BRI 3010 and BRI 6011.","date":"1995","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16535175","citation_count":17,"is_preprint":false},{"pmid":"21752865","id":"PMC_21752865","title":"Glycosylation of BRI2 on asparagine 170 is involved in its trafficking to the cell surface but not in its processing by furin or ADAM10.","date":"2011","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21752865","citation_count":16,"is_preprint":false},{"pmid":"18440095","id":"PMC_18440095","title":"BRI2 homodimerizes with the involvement of intermolecular disulfide bonds.","date":"2008","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/18440095","citation_count":16,"is_preprint":false},{"pmid":"11193182","id":"PMC_11193182","title":"Familial British dementia: expression and metabolism of BRI.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11193182","citation_count":14,"is_preprint":false},{"pmid":"25597881","id":"PMC_25597881","title":"Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.","date":"2015","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/25597881","citation_count":14,"is_preprint":false},{"pmid":"28176357","id":"PMC_28176357","title":"BRI2 Processing and Its Neuritogenic Role Are Modulated by Protein Phosphatase 1 Complexing.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28176357","citation_count":13,"is_preprint":false},{"pmid":"33814452","id":"PMC_33814452","title":"A Novel ITM2B Mutation Associated with Familial Chinese Dementia.","date":"2021","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/33814452","citation_count":13,"is_preprint":false},{"pmid":"26528887","id":"PMC_26528887","title":"Interaction of ApoE3 and ApoE4 isoforms with an ITM2b/BRI2 mutation linked to the Alzheimer disease-like Danish dementia: Effects on learning and memory.","date":"2015","source":"Neurobiology of learning and memory","url":"https://pubmed.ncbi.nlm.nih.gov/26528887","citation_count":13,"is_preprint":false},{"pmid":"38829730","id":"PMC_38829730","title":"Ligand Homogenized Br-I Wide-Bandgap Perovskites for Efficient NiO-Based Inverted Semitransparent and Tandem Solar Cells.","date":"2024","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/38829730","citation_count":13,"is_preprint":false},{"pmid":"38347225","id":"PMC_38347225","title":"Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer's and related dementias.","date":"2024","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/38347225","citation_count":12,"is_preprint":false},{"pmid":"25557390","id":"PMC_25557390","title":"The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25557390","citation_count":12,"is_preprint":false},{"pmid":"34330289","id":"PMC_34330289","title":"Expression of the human molecular chaperone domain Bri2 BRICHOS on a gram per liter scale with an E. coli fed-batch culture.","date":"2021","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/34330289","citation_count":12,"is_preprint":false},{"pmid":"29687167","id":"PMC_29687167","title":"BRI2 as an anti-Alzheimer gene.","date":"2018","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/29687167","citation_count":11,"is_preprint":false},{"pmid":"26515131","id":"PMC_26515131","title":"BRI2 and BRI3 are functionally distinct phosphoproteins.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26515131","citation_count":11,"is_preprint":false},{"pmid":"25336154","id":"PMC_25336154","title":"BRI2 ectodomain affects Aβ42 fibrillation and tau truncation in human neuroblastoma cells.","date":"2014","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/25336154","citation_count":11,"is_preprint":false},{"pmid":"18689990","id":"PMC_18689990","title":"Enrichment of human beta 1 bri/alpha 6 bri/CD71 dim keratinocytes after culture in defined media.","date":"2008","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/18689990","citation_count":11,"is_preprint":false},{"pmid":"31365883","id":"PMC_31365883","title":"A seminested RT-PCR for molecular genotyping of the Brazilian BR-I Infectious Bronchitis Virus Strain (GI-11).","date":"2019","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/31365883","citation_count":11,"is_preprint":false},{"pmid":"21849041","id":"PMC_21849041","title":"Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01).","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21849041","citation_count":11,"is_preprint":false},{"pmid":"36273719","id":"PMC_36273719","title":"S100A9 amyloid growth and S100A9 fibril-induced impairment of gamma oscillations in area CA3 of mouse hippocampus ex vivo is prevented by Bri2 BRICHOS.","date":"2022","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36273719","citation_count":9,"is_preprint":false},{"pmid":"15182222","id":"PMC_15182222","title":"Properties of neurotoxic peptides related to the Bri gene.","date":"2004","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/15182222","citation_count":9,"is_preprint":false},{"pmid":"32986959","id":"PMC_32986959","title":"Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP).","date":"2020","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32986959","citation_count":9,"is_preprint":false},{"pmid":"28131015","id":"PMC_28131015","title":"Amyloid and intracellular accumulation of BRI2.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28131015","citation_count":8,"is_preprint":false},{"pmid":"33192475","id":"PMC_33192475","title":"Analyses Mutations in GSN, CST3, TTR, and ITM2B Genes in Chinese Patients With Alzheimer's Disease.","date":"2020","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33192475","citation_count":8,"is_preprint":false},{"pmid":"25957407","id":"PMC_25957407","title":"The Familial British Dementia Mutation Promotes Formation of Neurotoxic Cystine Cross-linked Amyloid Bri (ABri) Oligomers.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25957407","citation_count":8,"is_preprint":false},{"pmid":"37038821","id":"PMC_37038821","title":"A Novel c.800G>C Variant of the ITM2B Gene in Familial Korean Dementia.","date":"2023","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/37038821","citation_count":7,"is_preprint":false},{"pmid":"16246057","id":"PMC_16246057","title":"Structure and neurotoxicity of novel amyloids derived from the BRI gene.","date":"2005","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/16246057","citation_count":7,"is_preprint":false},{"pmid":"38289121","id":"PMC_38289121","title":"MicroRNA-196a-5p facilitates the onset and progression via targeting ITM2B in esophageal squamous cell carcinoma.","date":"2024","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/38289121","citation_count":6,"is_preprint":false},{"pmid":"38980078","id":"PMC_38980078","title":"Specific inhibition of α-synuclein oligomer generation and toxicity by the chaperone domain Bri2 BRICHOS.","date":"2024","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/38980078","citation_count":6,"is_preprint":false},{"pmid":"37477586","id":"PMC_37477586","title":"Antigenic and molecular characterization of isolates of the Brazilian genotype BR-I (GI-11) of infectious bronchitis virus supports its recognition as BR-I serotype.","date":"2023","source":"Avian pathology : journal of the W.V.P.A","url":"https://pubmed.ncbi.nlm.nih.gov/37477586","citation_count":6,"is_preprint":false},{"pmid":"27867030","id":"PMC_27867030","title":"Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4+CD25bri regulatory T cells.","date":"2016","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27867030","citation_count":6,"is_preprint":false},{"pmid":"12196136","id":"PMC_12196136","title":"Properties of neurotoxic peptides related to the BRI gene.","date":"2002","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/12196136","citation_count":6,"is_preprint":false},{"pmid":"32826790","id":"PMC_32826790","title":"DEEP PHENOTYPING AND FURTHER INSIGHTS INTO ITM2B-RELATED RETINAL DYSTROPHY.","date":"2021","source":"Retina (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/32826790","citation_count":5,"is_preprint":false},{"pmid":"36935047","id":"PMC_36935047","title":"Identification of cytoskeletal proteins as binding partners of Bri2 BRICHOS domain.","date":"2023","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36935047","citation_count":4,"is_preprint":false},{"pmid":"34298087","id":"PMC_34298087","title":"Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan.","date":"2021","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34298087","citation_count":4,"is_preprint":false},{"pmid":"31731182","id":"PMC_31731182","title":"Generation of human induced pluripotent stem cell lines from a patient with ITM2B-related retinal dystrophy and a non mutated brother.","date":"2019","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31731182","citation_count":4,"is_preprint":false},{"pmid":"38117414","id":"PMC_38117414","title":"The Brazilian Toxoplasma gondii strain BRI caused greater inflammation and impairment in anxiogenic behavior in mice, which was reverted by rosuvastatin treatment.","date":"2023","source":"Parasitology research","url":"https://pubmed.ncbi.nlm.nih.gov/38117414","citation_count":4,"is_preprint":false},{"pmid":"25633876","id":"PMC_25633876","title":"Metal ion mediated transition from random coil to β-sheet and aggregation of Bri2-23, a natural inhibitor of Aβ aggregation.","date":"2015","source":"Metallomics : integrated biometal science","url":"https://pubmed.ncbi.nlm.nih.gov/25633876","citation_count":4,"is_preprint":false},{"pmid":"39962534","id":"PMC_39962534","title":"CircRNA Itm2b induces oxidative stress via the interaction with Sirt1-Nox4 to aggravate sleep disturbances after traumatic brain injury.","date":"2025","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/39962534","citation_count":4,"is_preprint":false},{"pmid":"40035576","id":"PMC_40035576","title":"Determinants for Substoichiometric Inhibition of IAPP and Aβ Amyloid Aggregations by Bri2 BRICHOS.","date":"2025","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/40035576","citation_count":3,"is_preprint":false},{"pmid":"41319268","id":"PMC_41319268","title":"ITM2B Truncation Promotes Migrasome Formation to Accelerate Renal Cell Carcinoma Growth.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41319268","citation_count":2,"is_preprint":false},{"pmid":"40042444","id":"PMC_40042444","title":"Assessing Co-Localization of ITM2B With Alzheimer's Disease and Limbic-Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Changes.","date":"2025","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/40042444","citation_count":2,"is_preprint":false},{"pmid":"33690096","id":"PMC_33690096","title":"The synthesis and characterization of Bri2 BRICHOS coated magnetic particles and their application to protein fishing: Identification of novel binding proteins.","date":"2021","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/33690096","citation_count":2,"is_preprint":false},{"pmid":"37473460","id":"PMC_37473460","title":"Generation of gene corrected human isogenic iPSC lines (IDVi003-A_CR13, IDVi003-A_CR21, IDVi003-A_CR24) from an inherited retinal dystrophy patient-derived IPSC line ITM2B-5286-3 (IDVi003-A) carrying the ITM2B c.782A > C variant using CRISPR/Cas9.","date":"2023","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37473460","citation_count":2,"is_preprint":false},{"pmid":"41224179","id":"PMC_41224179","title":"Bri2 BRICHOS, a molecular chaperone-like domain that can cross brain vascular endothelial cells and deliver proteins into neurons.","date":"2025","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/41224179","citation_count":2,"is_preprint":false},{"pmid":"40314981","id":"PMC_40314981","title":"Massive mutagenesis reveals an incomplete amyloid motif in Bri2 that turns amyloidogenic upon C-terminal extension.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40314981","citation_count":2,"is_preprint":false},{"pmid":"39559206","id":"PMC_39559206","title":"CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39559206","citation_count":2,"is_preprint":false},{"pmid":"38975736","id":"PMC_38975736","title":"Jmjd2c maintains the ALDHbri+ cancer stemness with transcription factor SOX2 in lung squamous cell carcinoma.","date":"2024","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38975736","citation_count":2,"is_preprint":false},{"pmid":"36312450","id":"PMC_36312450","title":"Safety and efficacy of a feed additive consisting of endo-1,4-β-xylanase produced by Komagataella phaffiiDSM 33574, and viable spores of Bacillus velezensisDSM 21836 and Bacillus licheniformisATCC 53757 (EnzaPro) for chickens for fattening, chickens reared for laying/breeding, turkeys for fattening, turkeys reared for breeding and growing minor poultry species (BioResource International (BRI), Inc.).","date":"2022","source":"EFSA journal. European Food Safety Authority","url":"https://pubmed.ncbi.nlm.nih.gov/36312450","citation_count":2,"is_preprint":false},{"pmid":"36322967","id":"PMC_36322967","title":"Imaging the Photodissociation Dynamics and Fragment Alignment of CH2BrI at 193 nm.","date":"2022","source":"The journal of physical chemistry. A","url":"https://pubmed.ncbi.nlm.nih.gov/36322967","citation_count":2,"is_preprint":false},{"pmid":"38473856","id":"PMC_38473856","title":"Myelin Basic Protein Attenuates Furin-Mediated Bri2 Cleavage and Postpones Its Membrane Trafficking.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38473856","citation_count":1,"is_preprint":false},{"pmid":"37398330","id":"PMC_37398330","title":"BRI2-mediated regulation of TREM2 processing in microglia and its potential implications for Alzheimer's disease and related dementias.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37398330","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50736,"output_tokens":7993,"usd":0.136051,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17541,"output_tokens":5554,"usd":0.113278,"stage2_stop_reason":"end_turn"},"total_usd":0.249329,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"A single base substitution at the stop codon of BRI generates a longer open reading frame producing a 277-residue precursor; furin-like proteolytic cleavage releases the 34 C-terminal amino acids as the ABri amyloid peptide, establishing the mechanism by which the FBD mutation causes amyloid generation.\",\n      \"method\": \"Molecular cloning, sequencing, restriction enzyme analysis, antibody characterization of isolated amyloid fibrils\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — discovery paper with molecular cloning, peptide isolation, restriction enzyme validation, and antibody recognition; independently replicated in multiple subsequent studies\",\n      \"pmids\": [\"10391242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A 10-nucleotide duplication in the 3' region of BRI2 causes a frameshift generating a larger precursor; furin cleavage releases the 34 C-terminal amino acid ADan peptide, which is deposited as amyloid in familial Danish dementia, establishing the same proteolytic release mechanism for a second BRI2 mutation.\",\n      \"method\": \"N-terminal sequence analysis of isolated amyloid fibrils, molecular genetic analysis, sequencing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct peptide sequencing from patient amyloid fibrils plus molecular genetic characterization; replicated by subsequent studies\",\n      \"pmids\": [\"10781099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BRI2 is constitutively processed by furin, which cleaves between residues 243 and 244 to release the C-terminal peptide; furin is the most efficient proprotein convertase for this processing, and the mutant BRI-L precursor generates elevated levels of peptides compared to wild-type.\",\n      \"method\": \"Cell-based expression of BRI and BRI-L with furin inhibitor (alpha1-antitrypsin Portland), comparison of multiple proprotein convertases (furin, PACE4, PC6A, PC6B, LPC)\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro processing assay with furin inhibitor and multiple convertases; replicated by Kim et al. 2001 (PMID 11709554)\",\n      \"pmids\": [\"11193182\", \"11709554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Furin processes both BRI and BRI-L (FBD mutant) and BRI-D (FDD mutant); the ADan peptide accumulates predominantly in intracellular compartments whereas ABri is detected both intracellularly and in the medium, suggesting intracellular accumulation drives neuronal damage.\",\n      \"method\": \"Inducible expression with furin inhibitor alpha1-antitrypsin Portland, comparison of proprotein convertases, intracellular/extracellular peptide detection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including furin inhibition and subcellular peptide localization; consistent with Kim et al. 2000\",\n      \"pmids\": [\"11709554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRI2 physically interacts with APP (amyloid-beta precursor protein); the interaction requires the transmembrane domain region (residues 648–719 of APP751 and residues 46–106 of BRI2), occurs in cis on the same cell membrane, and BRI2 expression inhibits APP processing, reducing secreted Abeta and AID levels.\",\n      \"method\": \"Co-immunoprecipitation in transfected and non-transfected cells, deletion mutagenesis, Abeta ELISA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with deletion mutants and functional Abeta measurement; independently replicated by Fotinopoulou et al. 2005 (PMID 16027166)\",\n      \"pmids\": [\"15983050\", \"16027166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRI2 interacts with APP via regions encompassing their full transmembrane domains; BRI2 presence increases cellular APP levels and beta-secretase-generated CTFs while decreasing alpha-secretase-generated CTFs and total secreted Abeta, indicating BRI2 modulates secretase access to APP.\",\n      \"method\": \"Co-immunoprecipitation in transfected HEK cells and primary neurons, deletion mutagenesis, Western blotting of APP processing fragments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — deletion mapping Co-IP plus multiple APP fragment readouts; consistent with Matsuda et al. 2005\",\n      \"pmids\": [\"16027166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BRI2 undergoes regulated intramembrane proteolysis: (1) ADAM10 sheds the BRI2 ectodomain (BRICHOS domain) into the extracellular space; (2) the remaining membrane-bound N-terminal fragment is then cleaved intramembranally by SPPL2a and SPPL2b (but not SPP or SPPL3), producing an intracellular domain and a secreted low-molecular-weight C-terminal peptide.\",\n      \"method\": \"Expression of all SPP/SPPL family members including loss-of-function variants in cells, Western blotting, co-expression with dominant-negative ADAM10\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic gain/loss-of-function with all family members; two-step cleavage mechanism established with multiple readouts\",\n      \"pmids\": [\"17965014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRI2 restricts docking of gamma-secretase to APP and blocks alpha- and beta-secretase access to their APP cleavage sequences; gene targeting (BRI2 knockout) increases Abeta levels in AD mouse models while transgenic BRI2 overexpression reduces them, establishing BRI2 as a physiological suppressor of Abeta production.\",\n      \"method\": \"Gene targeting (knockout mice), transgenic overexpression, in vivo Abeta quantification, cell-based secretase access assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain- and loss-of-function in vivo with defined molecular mechanism (secretase docking); replicated by Kim et al. 2008\",\n      \"pmids\": [\"18753367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Wild-type BRI2 reduces cerebral Abeta deposition in APP mouse models; the 23 amino acid peptide Bri2-23, released from BRI2 by normal furin processing, is present in human CSF, inhibits Abeta aggregation in vitro, and mediates the anti-amyloidogenic effect in vivo.\",\n      \"method\": \"Somatic brain transgenics, in vitro Abeta aggregation assay, CSF peptide detection\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic approach with in vitro aggregation validation; multiple orthogonal readouts\",\n      \"pmids\": [\"18524908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRI2 forms homodimers in cells via both non-covalent interactions and disulfide bridges between cysteines at position 89; dimers form in the ER and are present at the cell surface and in mouse brain.\",\n      \"method\": \"Non-reducing SDS-PAGE, co-immunoprecipitation, site-directed mutagenesis of Cys89, cell fractionation, mouse brain analysis\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis identifying specific cysteine plus Co-IP and fractionation; single lab\",\n      \"pmids\": [\"18440095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Mature BRI2 (but not immature forms) is transported to the plasma membrane and endosomes where it selectively interacts with mature APP; mature BRI2 inhibits APP processing by alpha-, beta-, and gamma-secretases specifically at the plasma membrane and in endocytic compartments.\",\n      \"method\": \"Live-cell imaging (FRAP), co-immunoprecipitation of mature vs. immature forms, subcellular fractionation, pharmacological inhibition of secretases\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (imaging, Co-IP with maturation distinction, fractionation, functional assays); single lab but rigorous\",\n      \"pmids\": [\"19748705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The extracellular BRICHOS domain of Bri2 (residues 90–236) binds to the ABri23 peptide and to Abeta1-40, and inhibits Abeta1-40 aggregation and fibril formation in vitro.\",\n      \"method\": \"Recombinant protein binding assay, Thioflavin T fibril formation assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding with recombinant protein plus functional aggregation assay; single lab, two orthogonal methods\",\n      \"pmids\": [\"20036644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The British BRI2 mutation drastically reduces expression of mature BRI2 protein in knock-in mice and in human FBD brains; this loss of BRI2 function causes severe hippocampal memory deficits independently of cerebral amyloidosis or tauopathy, as shown by the identical memory deficit in Bri2+/- heterozygous mice.\",\n      \"method\": \"Knock-in mouse model (FBD-KI), Bri2+/- heterozygous mice, behavioral memory testing, Western blotting for BRI2 protein levels in mouse and human brain\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetically congruous KI model plus heterozygous control with behavioral and biochemical readouts; loss-of-function phenotype defined\",\n      \"pmids\": [\"21048150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"APP/BRI2 complexes are reduced in synaptic membranes of FDD knock-in mice; APP haplodeficiency rescues memory and synaptic plasticity deficits in FDD-KI mice, establishing a functional genetic epistasis between BRI2 and APP in which BRI2 inhibits APP processing and APP metabolites mediate the synaptic/memory pathology.\",\n      \"method\": \"FDD knock-in x APP heterozygous cross (genetic epistasis), co-immunoprecipitation of synaptic membrane fractions, LTP measurements, behavioral memory testing\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with mechanistic Co-IP and electrophysiology; multiple orthogonal methods in one study\",\n      \"pmids\": [\"21587206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRI2 is N-glycosylated at asparagine 170; mutation of Asn170 to alanine reduces BRI2 trafficking to the cell surface and its steady-state plasma membrane levels, but does not affect cleavage by furin or ADAM10.\",\n      \"method\": \"Tunicamycin treatment, site-directed mutagenesis (N170A), cell surface biotinylation, pulse-chase 35S-methionine labeling\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis combined with pulse-chase and biotinylation; two orthogonal methods establishing glycosylation's specific role in trafficking but not processing\",\n      \"pmids\": [\"21752865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRI2 overexpression reduces extracellular Abeta by increasing levels of secreted insulin-degrading enzyme (IDE), a major Abeta-degrading protease; this effect is observed even with BRI2 lacking its C-terminal 23 amino acid peptide, suggesting BRI2 acts as a receptor that regulates IDE secretion.\",\n      \"method\": \"BRI2 overexpression in cells and AD mouse model, IDE ELISA and activity assay, Abeta measurement, BRI2 deletion constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion constructs plus IDE functional measurements; single lab, multiple readouts\",\n      \"pmids\": [\"21873424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The alpha-helical content of the BRI2 transmembrane domain (TMD) governs efficiency of intramembrane cleavage by SPPL2b: higher alpha-helical content reduces cleavage efficiency; a GXXXG dimerization motif has only minor influence; only one of four conserved intramembrane glycine residues significantly affects TMD secondary structure and intramembrane processing.\",\n      \"method\": \"Site-directed mutagenesis of TMD residues, circular dichroism spectroscopy, cell-based cleavage assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with CD spectroscopy and functional cleavage assay; mechanistic dissection of TMD determinants\",\n      \"pmids\": [\"22194595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRI2 interacts with BACE1 and decreases its cellular levels by promoting lysosomal (not proteasomal) degradation of BACE1; BRI2 also reduces BACE1 mRNA levels by ~50%, thereby reducing beta-cleavage of APP.\",\n      \"method\": \"Co-immunoprecipitation, lysosomal/proteasomal inhibitor experiments, RT-PCR for BACE1 mRNA, Western blotting of sAPPbeta\",\n      \"journal\": \"Current Alzheimer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus pharmacological dissection of degradation pathway and mRNA measurement; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23701002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BRI2 is a phosphoprotein and a protein phosphatase 1 (PP1) interacting protein; the BRI2:PP1 complex is formed in vitro and in vivo; disruption of the PP1-binding motif increases BRI2 phosphorylation; phosphorylated full-length BRI2 promotes formation of neuritic processes while the BRI2 N-terminal fragment (generated by ADAM10 processing) promotes neurite elongation.\",\n      \"method\": \"Co-immunoprecipitation in vitro and in vivo, PP1-binding motif mutagenesis, phosphorylation assays, ADAM10 inhibitor treatment, neurite outgrowth measurements in SH-SY5Y cells\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — validated Co-IP plus mutagenesis and functional neurite assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26515131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Bri2 BRICHOS domain monomers potently prevent neuronal network toxicity of Abeta42, while dimers strongly suppress Abeta fibril formation; high-molecular-weight oligomers efficiently inhibit non-fibrillar protein aggregation; these qualitatively distinct chaperone activities are governed by the quaternary assembly state of the BRICHOS domain.\",\n      \"method\": \"Recombinant Bri2 BRICHOS in defined oligomeric states, ThT fibril formation assays, hippocampal network oscillation electrophysiology, Drosophila in vivo model, electron microscopy\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (in vitro aggregation, electrophysiology, in vivo), dissection by defined assembly states; replicated and extended in subsequent work\",\n      \"pmids\": [\"29234026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRI2 phosphorylation state (regulated by the BRI2:PP1 complex) is an important regulatory mechanism for its proteolytic processing and neuritogenic role; phosphorylated full-length BRI2 is important for neuritic process formation, while BRI2 NTF (produced by ADAM10 processing) promotes neurite elongation.\",\n      \"method\": \"PP1-binding motif mutant transfection in SH-SY5Y cells, ADAM10 inhibitor treatment, neurite outgrowth quantification, Western blotting\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis combined with pharmacological inhibition and functional assay; single lab\",\n      \"pmids\": [\"28176357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The BRICHOS domain of Bri2 inhibits IAPP fibril formation in vitro and redirects IAPP into amorphous aggregates; Bri2 colocalizes with IAPP intracellularly in human beta cells; siRNA knockdown of endogenous Bri2 increases sensitivity to metabolic stress and cell death; overexpression of Bri2 BRICHOS is protective against IAPP toxicity in human beta cells and in a Drosophila model.\",\n      \"method\": \"siRNA knockdown, Bri2 overexpression, in vitro ThT fibril assay, cell viability assay, Drosophila survival assay, immunofluorescence colocalization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function in two experimental systems (human cells and Drosophila) plus in vitro mechanistic assay; multiple orthogonal approaches\",\n      \"pmids\": [\"29507232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ITM2B/BRI2 has dual presynaptic and postsynaptic roles in glutamatergic transmission: conditional deletion of Itm2b in CA3 neurons decreases spontaneous glutamate release probability and increases short-term synaptic facilitation, while deletion in CA1 neurons decreases AMPAR-mediated postsynaptic responses.\",\n      \"method\": \"Conditional neuron-specific Cre-mediated Itm2b knockout in hippocampal Schaffer-collateral pathway (CA3, CA1, or both), electrophysiology (spontaneous EPSCs, AMPAR responses, short-term plasticity)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with defined electrophysiological phenotypes dissecting pre- vs. postsynaptic contributions\",\n      \"pmids\": [\"30890756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ITM2B physically interacts with the urate transporter GLUT9 (SLC2A9), identified by dual-membrane yeast two-hybrid, and confirmed by co-immunoprecipitation in transfected HEK293T cells; ITM2B inhibits GLUT9-mediated urate uptake and stimulates urate efflux; ITM2B variants linked to familial Danish dementia significantly attenuate inhibition of GLUT9-mediated urate influx.\",\n      \"method\": \"Dual-membrane yeast two-hybrid, co-immunoprecipitation in HEK293T cells and Xenopus oocytes, urate transport assays in oocytes, glycosylation mutant analysis\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus functional transport assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31695625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FDD and FBD pathogenic mutations in ITM2b alter maturation of BRI2 resulting in reduced levels of functional mature BRI2 protein at synapses, leading to reduced spontaneous glutamate release, decreased AMPAR-mediated responses, and increased short-term synaptic facilitation — phenotypes matching those of Itm2b knockout mice, establishing loss of BRI2 synaptic function as a pathogenic mechanism.\",\n      \"method\": \"FDD and FBD knock-in mice, in vivo and in vitro maturation assays, electrophysiology in hippocampal slices\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in models genetically congruous to human disease with biochemical and electrophysiological readouts; consistent with prior work\",\n      \"pmids\": [\"33172889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NRBP1, a substrate receptor of a heterodimeric Cullin-RING ubiquitin ligase (CRL) containing both Cul2 and Cul4A, targets BRI2 (and BRI3) for ubiquitin-mediated degradation; NRBP1 dimerizes and assembles the CRL through its BC-box and cryptic H-box; chaperone-like TSC22D3 and TSC22D4 enhance NRBP1 CRL formation; NRBP1 knockdown in neuronal cells increases BRI2/BRI3 abundance and significantly reduces Abeta production.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, NRBP1 knockdown in neuronal cells, Abeta ELISA, mass spectrometry interactome\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — identified CRL components by MS, validated by Co-IP, mutagenesis of BC-box/H-box, and loss-of-function with functional Abeta readout\",\n      \"pmids\": [\"32160551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A R221E mutant of Bri2 BRICHOS forms stable monomers; introducing R221E partially disassembles wild-type Bri2 BRICHOS oligomers into monomers, potentiating their ability to prevent Abeta42 neurotoxicity to neuronal network activity, demonstrating that the chaperone activity of endogenous Bri2 BRICHOS can be augmented by modulating assembly state.\",\n      \"method\": \"Site-directed mutagenesis, analytical ultracentrifugation, hippocampal network oscillation electrophysiology, ThT fibril formation assay\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis defining oligomeric state plus functional electrophysiology readout; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"31959875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ITM2B(s), a short cytoplasmic/mitochondrial isoform of ITM2B containing a BH3 domain, induces apoptosis upon IL-2 deprivation and interacts with the anti-apoptotic protein Bcl-2; mutation of the critical L and D residues within the BH3 domain abolishes its pro-apoptotic activity.\",\n      \"method\": \"Cloning and overexpression of ITM2B(s), co-immunoprecipitation with Bcl-2, BH3 domain mutagenesis, cell viability assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with Bcl-2 and BH3 mutagenesis establishing domain requirement; single lab, two orthogonal methods\",\n      \"pmids\": [\"12082633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRI2 directly interacts with TREM2 protein (confirmed by cell-free ectodomain binding with recombinant proteins), inhibits alpha-secretase-mediated TREM2 processing in cells and in vivo; constitutive and microglial-specific Itm2b-KO mice show increased TREM2-CTF and sTREM2; BRI2 also boosts Trem2 mRNA expression and influences Trem2 protein levels through alpha-secretase-independent pathways.\",\n      \"method\": \"Cell-free direct binding of recombinant BRI2 and TREM2 ectodomains, co-immunoprecipitation in heterologous cells, constitutive and conditional (microglial-specific) Itm2b knockout mice, single-cell RNA-sequencing, Western blotting and ELISA for TREM2 processing products\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-free direct binding plus multiple in vivo genetic models (constitutive KO and cell-type-specific KO) with multiple processing readouts\",\n      \"pmids\": [\"38347225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Myelin basic protein (MBP) covers a significant portion of the Bri2 ectodomain (including the furin cleavage site) and attenuates furin-mediated Bri2 C-terminal peptide cleavage; MBP co-expression also restricts Bri2 membrane trafficking independently of the furin cleavage suppression.\",\n      \"method\": \"Molecular dynamics simulation of MBP-Bri2 complex, co-expression of MBP with Bri2 and mutants in mammalian cells, Western blotting for processing products, subcellular localization analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cell-based functional assay with localization readout supported by molecular dynamics; single lab, in silico plus cell-based\",\n      \"pmids\": [\"38473856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Using a massively parallel yeast-based assay, the amyloid-forming core of ADan fibrils was mapped to positions 20–26 of the C-terminal peptide (where stop-loss extension occurs); ~32% of random C-terminal extensions of Bri2 can nucleate amyloid, showing the Bri2 C-terminus contains an incomplete amyloid motif that becomes amyloidogenic upon extension — providing a mechanism for pathogenic stop-loss mutations.\",\n      \"method\": \"Yeast-based massively parallel amyloid formation assay (676 ADan substitutions and ~18,000 random C-terminal extensions), systematic amyloid scoring\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis at scale with quantitative amyloid readout defining the amyloid core; single study but high-throughput and rigorous\",\n      \"pmids\": [\"40314981\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ITM2B/BRI2 is a type II transmembrane protein that undergoes sequential proteolytic processing: furin cleaves the C-terminus to release the normal Bri2-23 peptide (or pathological ABri/ADan peptides from mutant precursors), ADAM10 sheds the ectodomain (BRICHOS domain), and SPPL2a/SPPL2b perform intramembrane cleavage of the remaining N-terminal fragment; mature BRI2 directly binds APP at their transmembrane domains in cis on the plasma membrane and in endosomes, sterically blocking alpha-, beta-, and gamma-secretase access to APP to suppress Abeta production, and also directly binds and inhibits processing of TREM2 by alpha-secretase in microglia; the released BRICHOS domain acts as an assembly-state-dependent molecular chaperone (monomers suppress Abeta toxicity, dimers suppress fibril formation, oligomers inhibit non-fibrillar aggregation); BRI2 is additionally regulated post-translationally by N-glycosylation at Asn170 (required for plasma membrane trafficking), phosphorylation governed by a BRI2:PP1 complex (which controls neuritogenesis and processing), and ubiquitin-mediated degradation via the NRBP1-containing CRL2/CRL4A ligase; loss of BRI2 function impairs both presynaptic glutamate release and postsynaptic AMPAR responses, causing synaptic and memory deficits, while pathogenic FBD/FDD mutations reduce mature BRI2 protein levels, identifying loss-of-function as a key pathogenic mechanism independent of amyloid deposition.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ITM2B/BRI2 is a type II transmembrane protein that physiologically suppresses amyloidogenic processing and supports synaptic function in the brain [#7, #22]. Mature BRI2 reaches the plasma membrane and endosomes and binds APP in cis through their transmembrane domains, sterically restricting alpha-, beta-, and gamma-secretase access to APP and thereby lowering Abeta production [#4, #5, #10]; genetic loss of BRI2 raises Abeta in vivo while overexpression lowers it [#7, #8]. BRI2 also broadens its amyloid-suppressing reach by reducing BACE1 levels, by acting as a receptor that elevates secreted insulin-degrading enzyme, and by directly binding TREM2 in microglia to limit its alpha-secretase processing [#17, #15, #28]. BRI2 is matured by sequential proteolysis: furin cleaves the C-terminus to liberate the anti-aggregant Bri2-23 peptide, ADAM10 sheds the BRICHOS ectodomain, and SPPL2a/SPPL2b carry out intramembrane cleavage of the residual N-terminal fragment [#2, #6, #8]. The released BRICHOS domain is an assembly-state-dependent chaperone whose monomers block Abeta42 neurotoxicity, dimers suppress fibril formation, and oligomers inhibit non-fibrillar aggregation, with activity extending to IAPP [#19, #26, #21]. BRI2 function and trafficking are tuned by N-glycosylation at Asn170, by a BRI2:PP1 phosphorylation complex that governs neuritogenesis, and by NRBP1-containing CRL2/CRL4A-mediated ubiquitin degradation [#14, #18, #25]. The familial British and Danish dementia mutations cause C-terminal stop-loss/frameshift extensions that release the amyloidogenic ABri and ADan peptides via the same furin step while drastically reducing mature functional BRI2 at synapses, establishing loss of BRI2 synaptic function—impaired glutamate release and AMPAR responses—as a pathogenic mechanism independent of amyloid deposition [#0, #1, #12, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established how a BRI2 disease mutation produces amyloid, answering what molecular lesion underlies familial British dementia.\",\n      \"evidence\": \"Molecular cloning, sequencing, and antibody analysis of isolated amyloid fibrils identifying a stop-codon substitution that extends the ORF and a furin-released 34-residue ABri peptide\",\n      \"pmids\": [\"10391242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define BRI2's normal physiological function\", \"Did not establish whether amyloid or protein loss drives disease\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Generalized the proteolytic-release mechanism to a second mutation, showing a frameshift duplication produces the ADan amyloid peptide in familial Danish dementia.\",\n      \"evidence\": \"N-terminal sequencing of patient amyloid fibrils plus molecular genetic analysis\",\n      \"pmids\": [\"10781099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Subcellular site of peptide accumulation not resolved\", \"Normal BRI2 function still unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified furin as the constitutive protease cleaving BRI2 and showed mutant precursor yields elevated peptide, defining the enzymatic step that liberates the C-terminal peptides.\",\n      \"evidence\": \"Cell-based expression of BRI/BRI-L with furin inhibitor and comparison across proprotein convertases; replicated subcellular localization showing ADan accumulates intracellularly\",\n      \"pmids\": [\"11193182\", \"11709554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address whether furin processing is regulated\", \"Other proteolytic steps not yet identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Proposed a pro-apoptotic role for a short ITM2B isoform, raising the question of whether BRI2 participates in cell death regulation.\",\n      \"evidence\": \"Overexpression of ITM2B(s), Co-IP with Bcl-2, and BH3-domain mutagenesis with viability assays\",\n      \"pmids\": [\"12082633\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of the short isoform not established\", \"Not linked to the neuronal/synaptic functions later defined\", \"Single lab, not independently confirmed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed BRI2's normal function as a cis-binding inhibitor of APP, answering how it could suppress Abeta production.\",\n      \"evidence\": \"Reciprocal Co-IP with deletion mutants mapping the transmembrane interaction and Abeta ELISA/CTF Western blots in cells and primary neurons\",\n      \"pmids\": [\"15983050\", \"16027166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance not yet demonstrated\", \"Which secretases are blocked at which compartments unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the full maturation pathway by identifying ADAM10 ectodomain shedding followed by SPPL2a/SPPL2b intramembrane cleavage.\",\n      \"evidence\": \"Systematic gain/loss-of-function across all SPP/SPPL family members and dominant-negative ADAM10 with Western blot fragment readouts\",\n      \"pmids\": [\"17965014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functions of the released fragments not yet defined\", \"Regulation of these cleavages unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated in vivo that BRI2 is a physiological Abeta suppressor and that the furin-released Bri2-23 peptide mediates the anti-amyloidogenic effect.\",\n      \"evidence\": \"BRI2 knockout and transgenic overexpression in AD mouse models, in vitro Abeta aggregation assays, secretase-access assays, and CSF peptide detection\",\n      \"pmids\": [\"18753367\", \"18524908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate amyloid-suppression from any independent BRI2 functions\", \"Synaptic role not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Refined the mechanism to mature BRI2 acting at the plasma membrane/endosomes, and showed BRI2 homodimerizes via Cys89.\",\n      \"evidence\": \"FRAP imaging, maturation-discriminating Co-IP and fractionation, and Cys89 mutagenesis on non-reducing gels\",\n      \"pmids\": [\"19748705\", \"18440095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of dimerization for APP inhibition not defined\", \"Dimerization data from single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Separated amyloid deposition from disease by showing the British mutation reduces mature BRI2 and that haploinsufficiency alone causes memory deficits.\",\n      \"evidence\": \"FBD knock-in and Bri2+/- heterozygous mice with behavioral testing and Western blots in mouse and human FBD brain\",\n      \"pmids\": [\"21048150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the memory deficit not yet mapped to a pathway\", \"Synaptic mechanism not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established genetic epistasis placing APP metabolites downstream of BRI2 loss in synaptic/memory pathology and added trafficking, IDE, and BACE1 regulatory layers.\",\n      \"evidence\": \"FDD-KI x APP-heterozygous cross with LTP and behavior; Asn170 glycosylation mutagenesis with biotinylation/pulse-chase; IDE deletion-construct experiments; BRICHOS-Abeta binding/ThT assays\",\n      \"pmids\": [\"21587206\", \"21752865\", \"21873424\", \"20036644\", \"22194595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of direct APP inhibition vs IDE/BACE1 routes not quantified\", \"Some regulatory mechanisms from single labs\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed BRI2 lowers BACE1 by promoting lysosomal degradation and reducing its mRNA, broadening how BRI2 limits beta-cleavage of APP.\",\n      \"evidence\": \"Co-IP, lysosomal/proteasomal inhibitor experiments, BACE1 RT-PCR, and sAPPbeta Western blotting\",\n      \"pmids\": [\"23701002\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking BRI2 to BACE1 transcription unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved BRICHOS chaperone behavior as assembly-state-dependent and linked phosphorylation to processing and neuritogenesis.\",\n      \"evidence\": \"Recombinant BRICHOS in defined oligomeric states with ThT, hippocampal network electrophysiology, Drosophila, and EM; PP1-binding-motif mutagenesis with neurite assays\",\n      \"pmids\": [\"29234026\", \"28176357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of specific BRICHOS assembly states not fully established\", \"Phosphorylation findings from single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended BRICHOS chaperone activity to IAPP and showed endogenous Bri2 protects beta cells from amyloid toxicity, indicating a general anti-amyloid function.\",\n      \"evidence\": \"siRNA knockdown and BRICHOS overexpression in human beta cells and Drosophila, in vitro ThT, and colocalization\",\n      \"pmids\": [\"29507232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous relevance to diabetes pathology in humans not established\", \"Mechanism of intracellular Bri2-IAPP colocalization unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined dual presynaptic and postsynaptic roles for ITM2B in glutamatergic transmission and added a candidate non-amyloid interactor, GLUT9.\",\n      \"evidence\": \"Cell-type-specific conditional Itm2b knockout in CA3/CA1 with electrophysiology; dual-membrane Y2H and Co-IP plus urate transport assays for GLUT9\",\n      \"pmids\": [\"30890756\", \"31695625\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular effector linking BRI2 to glutamate release and AMPAR responses unknown\", \"GLUT9 interaction from single lab without in vivo confirmation\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Unified loss-of-function as the disease mechanism by showing FDD/FBD mutations reduce mature synaptic BRI2 and phenocopy knockout; identified NRBP1-CRL ubiquitin degradation and augmentable BRICHOS chaperone state.\",\n      \"evidence\": \"FDD/FBD knock-in mice with maturation assays and hippocampal-slice electrophysiology; NRBP1 CRL component MS/Co-IP/ubiquitination with Abeta readout; R221E BRICHOS monomerization with AUC and electrophysiology\",\n      \"pmids\": [\"33172889\", \"32160551\", \"31959875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals regulating NRBP1-mediated BRI2 turnover unknown\", \"Therapeutic feasibility of modulating BRICHOS assembly in vivo untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded BRI2's substrate repertoire to TREM2 in microglia and identified MBP as a regulator of furin processing and trafficking.\",\n      \"evidence\": \"Cell-free recombinant ectodomain binding, constitutive and microglial-specific Itm2b knockouts, scRNA-seq, and TREM2 processing readouts; MBP-Bri2 molecular dynamics plus co-expression cell assays\",\n      \"pmids\": [\"38347225\", \"38473856\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of BRI2-TREM2 regulation for microglial biology not fully defined\", \"MBP regulation mechanism from a single in silico/cell study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided a sequence-level mechanism for pathogenic stop-loss mutations by mapping the ADan amyloid core and showing the Bri2 C-terminus harbors an incomplete amyloid motif that becomes amyloidogenic on extension.\",\n      \"evidence\": \"Massively parallel yeast-based amyloid assay scoring hundreds of ADan substitutions and thousands of random C-terminal extensions\",\n      \"pmids\": [\"40314981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Yeast amyloid scores require validation in mammalian/neuronal context\", \"Does not address how extension interacts with the loss-of-function pathway\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular effectors that couple BRI2 to presynaptic glutamate release and postsynaptic AMPAR responses, and how its many regulatory inputs are integrated in vivo, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No identified synaptic effector downstream of BRI2\", \"No structure of the BRI2-APP transmembrane complex\", \"Physiological balance among APP, TREM2, IDE, BACE1, and GLUT9 interactions not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 7, 17, 28]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [19, 21, 26]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [11, 19, 21]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 10, 14]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 6, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 12, 24]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [22, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"complexes\": [\n      \"BRI2:PP1 complex\",\n      \"BRI2-APP transmembrane complex\",\n      \"NRBP1 CRL2/CRL4A ubiquitin ligase\"\n    ],\n    \"partners\": [\n      \"APP\",\n      \"TREM2\",\n      \"BACE1\",\n      \"PP1\",\n      \"NRBP1\",\n      \"SLC2A9\",\n      \"BCL2\",\n      \"ADAM10\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}